Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NexgenRxNEGXF 40 5-Year Yield-on-Cost % is 2.25 as of Jul. 24, 2026, which is 36% below its 10-year median of 3.53. GuruFocus rates NEGXF with a GF Score™ of 40/100 and a GF Value™ of $0.27 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 277 Healthcare Providers & Services companies, NexgenRx ranks worse than 71.12% on this metric.
NexgenRx's yield on cost for the quarter that ended in Mar. 2026 was 2.25.
The historical rank and industry rank for NexgenRx's 5-Year Yield-on-Cost % or its related term are showing as below:
NEGXF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.3 Med: 3.53 Max: 5
Current: 2.25
During the past 13 years, NexgenRx's highest Yield on Cost was 5.00. The lowest was 1.30. And the median was 3.53.
NEGXF's 5-Year Yield-on-Cost % is ranked worse than 71.12% of 277
companies
in the Healthcare Providers & Services industry
Industry Median: 2.9
vs NEGXF: 2.25
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
NexgenRx 5-Year Yield-on-Cost % Related Terms
NEGXF vs VEEV, BTSG, TEM: 5-Year Yield-on-Cost % Comparison
For the Health Information Services subindustry, NexgenRx's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NexgenRx 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NexgenRx's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where NexgenRx's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of NexgenRx is calculated as
NexgenRx (NEGXF) has a 5-Year Yield-on-Cost % of 2.25 as of Jul. 24, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on NexgenRx and its competitors. This is 36% below median its historical median of 3.53. Over the past decade, NexgenRx's 5-Year Yield-on-Cost % has ranged from 1.30 to 5.00. According to the industry distribution chart, NexgenRx ranks #197 out of 277 companies in the Healthcare Providers & Services industry, placing it in the top 71.1%.
Is NexgenRx's 5-Year Yield-on-Cost % too high?
NexgenRx's current 5-Year Yield-on-Cost % of 2.25 is 36% below median its 10-year median of 3.53. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 5.00. The Healthcare Providers & Services industry median 5-Year Yield-on-Cost % is 2.90. NexgenRx's value of 2.25 is 22.4% below this industry median. Based on the distribution chart, NexgenRx ranks #197 out of 277 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, NexgenRx has a GF Score™ of 40/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's 5-Year Yield-on-Cost % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NexgenRx ranks #197 out of 277 companies for 5-Year Yield-on-Cost %. This places NexgenRx in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.90. NexgenRx's value of 2.25 is 22.4% below this benchmark. Historically, NexgenRx's own 5-Year Yield-on-Cost % has ranged from 1.30 to 5.00 over the past decade. While the company's 10-year median is 3.53 vs. the industry median of 2.90, NexgenRx has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.90, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NexgenRx's current 5-Year Yield-on-Cost % of 2.25 is 22.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on NexgenRx and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NexgenRx's current 5-Year Yield-on-Cost % is 2.25, which is 36% below median its own 10-year median of 3.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (NEGXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $0.33 — trading 20.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 2.25, which is 36% below median its 10-year median of 3.53 and 22.4% below the Healthcare Providers & Services industry median of 2.90. NexgenRx's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For NexgenRx (NEGXF), the current 5-Year Yield-on-Cost % is 2.25 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NexgenRx (NEGXF) Overvalued in 2026?
Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued.
The current stock price of $0.33 is trading 20.4% above its estimated GF Value™ of $0.27.
GuruFocus considers NexgenRx to be Modestly Overvalued.
Key valuation signals for NEGXF:
5-Year Yield-on-Cost %: 2.25 (36% below median its 10-year median of 3.53)
GF Value™: $0.27 vs. price of $0.33 (20.4% above fair value)
Industry Position: 22.4% below the Healthcare Providers & Services median (#197 of 277)
No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
40GF Score
Get the complete analysis for NEGXF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEGXF has been successfully added to your 
